Related Experiment Video

Updated: Jun 18, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Study of a ligand complexed with Cdk2/Cdk4 by computer simulation

Yongjun Jiang1, Jianwei Zou, Chunshan Gui

  • 1Key Laboratory for Molecular Design and Nutrition Engineering, Ningbo Institute of Technology, Zhejiang University, Ningbo, 315104, P.R. China. yjjiang@nit.net.cn

Journal of Molecular Modeling
|June 2, 2005
PubMed

Insights

The drug NU6102 selectively targets cyclin-dependent kinase 2 (Cdk2) over Cdk4 due to interactions involving residue Asp86 and the ligand's sulfonamide group, aiding cancer treatment strategies.

Area of Science:

  • Molecular biology
  • Structural biology
  • Pharmacology

Background:

  • Cyclin-dependent kinases (Cdks) regulate the cell cycle.
  • Cdk inhibitors are investigated as cancer therapeutics.
  • NU6102 exhibits differential affinity for Cdk2 and Cdk4.

Purpose of the Study:

  • To elucidate the molecular basis of NU6102 selectivity between Cdk2 and Cdk4.
  • To understand the interaction mechanisms driving selective binding.

Main Methods:

  • Homology modeling to build Cdk4-NU6102 complex structure.
  • Molecular docking and dynamics simulations.
  • Free-energy calculations for binding affinity analysis.

Main Results:

  • A 3D model of the Cdk4-NU6102 complex was successfully generated.
  • Residue Asp86 was identified as critical for differential recognition between Cdk2 and Cdk4.
  • Favorable van der Waals interactions and nonpolar solvent contributions were observed.
  • The sulfonamide group of NU6102 is crucial for selective binding.

Conclusions:

  • The study provides a rational explanation for NU6102's selectivity.
  • Understanding these interactions can guide the design of more selective Cdk inhibitors for cancer therapy.

More Related Videos

Analyzing Protein Architectures and Protein-Ligand Complexes by Integrative Structural Mass Spectrometry07:33

Analyzing Protein Architectures and Protein-Ligand Complexes by Integrative Structural Mass Spectrometry

Published on: October 15, 2018

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Related Concept Videos

Crystal Field Theory - Octahedral Complexes02:58

Crystal Field Theory - Octahedral Complexes

Crystal Field Theory
To explain the observed behavior of transition metal complexes (such as colors), a model involving electrostatic interactions between the electrons from the ligands and the electrons in the unhybridized d orbitals of the central metal atom has been developed. This electrostatic model is crystal field theory (CFT). It helps to understand, interpret, and predict the colors, magnetic behavior, and some structures of coordination compounds of transition metals.
CFT focuses on...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...